Precision healthcare focus IPM.ai specializes in transforming real world data into insights to accelerate precision therapies for specialty and rare diseases, indicating strong selling points for life sciences companies seeking faster, lower-risk commercialization.

Real world data scale With access to a real world data universe of over 300 million de-identified patient journeys and 65 billion health signals, there are clear upsell opportunities to expand data partnerships, analytics services, or custom studies for drug development and launch programs.

Part of Real Chemistry As an arm of Real Chemistry, IPM.ai benefits from integrated capabilities and credibility, suggesting joint sales motions with broader services such as clinical, commercial strategy, and digital advertising offerings.

Recent collaborations Recent partnerships with Boston Children’s Hospital and recognition in data science and innovation provide social proof and a potential pathway to pursue academic medical centers and large pharma collaborations for real world evidence projects.

Financial and growth signals Revenue range of 1–10 million and a mid-sized employee base imply a scalable footprint suitable for tiered partnerships, pilots, and expansion agreements with mid-market life sciences firms seeking cost-effective analytics solutions.